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Abstract
Background:  Several studies have linked apolipoprotein E (ApoE) ε4 allele with elevated
cholesterol and blood pressure levels. Data on the association of APOE genotypes with blood
pressure, lipids, atrial fibrillation and ECG abnormalities in individuals aged 85 years and over is
sparse.
Methods: This cross sectional study consisted of all residents of the city of Vantaa (N = 601) aged
85 years or over of whom 505 participated in the study. Blood pressure was measured by using
mercury sphygmomanometer. 12-Lead ECG, short ambulatory ECG, or both were taken from all
study subjects to diagnose atrial fibrillation (AF). Ambulatory ECG was carried out home or in the
institute. APOE genotyping was performed using a combination of the polymerase chain reaction
(PCR) and solid-phase minisequencing technique. Statistical analysis was made by using Kruskall-
Wallis-test (continuous data) and χ2-test (rates and proportions).
Results: In these very elderly individuals, APOE 4 allele was significantly associated with elevated
cholesterol and low-density lipoprotein (LDL) levels. Blood pressure or cardiac arrhythmias did not
differ between APOE genotypes.
Conclusions:  These observations suggest that the important role of APOE genotype still
influences cardiovascular risk profile even among the very elderly people.
Background
Apolipoprotein E (ApoE) has an important role in the reg-
ulation of plasma cholesterol concentration. It also medi-
ates the receptor uptake of triglyceride rich lipoproteins
and may participate in reverse cholesterol transport [1,2].
ApoE is polymorphic and exists in three protein isoforms
designated E2, E3, and E4, [1,2] encoded by three alleles
ε2, ε3 and ε4 [3]. Genotypes ε4/ε4 and ε4/ε3 are associ-
ated with a high cholesterol concentration [4,5]. Thus
ApoE polymorphism may influence the risk of atheroscle-
rosis [4]. An association between the APOE ε4 and ε2 alle-
les with high blood pressure, and especially, with high
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systolic blood pressure has been observed [6,7]. However,
lack of association with high blood pressure has also been
reported [8-10].
Methods
The Vantaa 85+ Study is a longitudinal population based
study examining all residents of Vantaa, a city in Southern
Finland, aged 85 years or over (N = 601) on April the first
1991. All persons whether living home or in institutions
was asked to participate in the study. Altogether 553
(92%) consented in the study, 36 persons had died, 11
persons refused to participated and one could not be
reached. Of these 553 clinically examined subjects, APOE
genotyping was available from 531 (88.4%) subjects
blood pressure measurement from 521 (86.7%) and both
from 505 (84.0%). The Ethics Committee of the Helsinki
University Central Hospital approved the study. An
informed consent was obtained from all participants or
from a close relative if a participant was demented.
A physician performed structured interviews including a
history of cardiovascular symptoms and treatment. The
data was also collected from a computerised primary
health care record database. Physical examination of the
subjects included cardiac auscultation and measurement
of blood pressure and pulse rate. Blood pressure (systolic
Korotkoff phase I and diastolic phase V) was measured
with a calibrated mercury sphygmomanometer with the
cuff on the right arm, the subject sitting after having rested
for five minutes. The blood pressure of bedridden patients
was measured in a recumbent position.
The analysis of ECG recordings included evaluation of
arrhythmias and conduction abnormalities. Evaluation of
the signs of coronary heart disease (CHD) was not per-
formed. ECG recordings were performed with two meth-
ods. An ambulatory ECG monitoring technique with
three exploring electrodes corresponding to leads V1 and
V5 was used in 301 subjects and it was carried out at home
or in the institute. The recording period ranged from 30
minutes to two hours with an average monitoring time of
one hour. All the recordings were further analysed by the
Reynolds TR1-Holter analysing equipment. Accuracy of
reading was evaluated by analysing 10 registrations twice,
there were no differences between these two analyses.
Routine twelve lead resting ECGs were available from 204
subjects. One specialist performed all analyses.
Total serum cholesterol, high density lipoproteins (HDL),
low density lipoproteins (LDL) and triglycerides were
quantified by enzymatic techniques. APOE genotyping
was performed using a combination of the polymerase
chain reaction (PCR) and solid-phase minisequencing
technique [11].
Statistical analysis was made by using Kruskall-Wallis-test
(continuous data) and χ2-test (rates and proportions),
with 7 SPSS for Windows program. No adjustment for
multiple comparisons was made.
Results
The mean age of the study population (N = 505) was 88.3
years (range 85–104 years). 107 (21.2%) were males and
398 (78.8%) females. The distribution of APOE allele fre-
quencies were ε4 15.3%, ε3 76.9%, and ε2 7,8%. These
frequencies follow Hardy-Weinberg equilibrium, and
agree with the previously reported allele frequencies in the
elderly Finnish population [12].
The mean systolic and diastolic blood pressures were 149
mmHg (range 90–230 mmHg) and 82 mmHg (range 45–
120 mmHg), respectively. There was no association
between systolic or diastolic blood pressure level and
APOE genotypes (Table 1). As previously shown [13] total
serum cholesterol levels differed significantly between dif-
ferent APOE genotypes, with ε3/ε4 and ε4/ε4 being asso-
ciated with the highest levels (Table 2, P = 0.02). Also high
LDL cholesterol level associated with ε3/ε4 and ε4/ε4 (P =
0.001). The levels of triglycerides, or HDL cholesterol
showed no association with APOE genotypes.
Table 1: Systolic and diastolic blood pressures, and APOE genotypes in the study population (N = 505). MmHg ± SD.
APOE genotype N(%) in study population Mean systolic BP Mean diastolic BP
ε2/ε2 2 (0.4) 150 ± 14.1 85 ± 7.1
ε2/ε3 62 (12.3) 149 ± 25.5 81 ± 12.0
ε2/ε4 14 (2.8) 141 ± 32.1 76 ± 13.4
ε3/ε3 294 (58.2) 150 ± 28.1 81 ± 13.2
ε3/ε4 126 (24.9) 147 ± 27.3 82 ± 12.3
ε4/ε4 7 (1.4) 132 ± 27.3 82 ± 8.1
P 0.5 0.7
Total 505 (100)BMC Geriatrics 2004, 4 http://www.biomedcentral.com/1471-2318/4/1
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APOE genotypes and ECG abnormalities are shown in
table 3. The genotype ε3/ε3 seemed to be associated with
the highest frequencies of chronic atrial fibrillation (AF)
but the difference was of borderline statistical significance
only. Extrasystolias or conduction disturbances were not
associated with the APOE genotypes. There were also no
differences between males and females regarding APOE
and AF, blood pressure or lipids.
Discussion
The association of various APOE genotypes with some
prevalent diseases such as atherosclerosis and Alzheimer's
disease has drawn a lot of attention during the last decade.
Previous studies have consistently shown that APOE gen-
otype contributes to cholesterol levels [3,5]. The present
study shows that APOE genotype affects serum cholesterol
and LDL-levels in the very elderly. However, there was no
association between APOE genotype and some other car-
diovascular risk factors such as systolic or diastolic blood
pressure, and serum triglycerides. Although the occur-
rence of AF was higher in individuals with allele ε3, there
were no statistically significant relationships between
APOE genotype and the presence of arrhythmias or con-
duction abnormalities.
It is well known that the ε4 allele of APOE is associated
with the increased prevalence of atherosclerosis and CHD
[4,13,14]. However, there are controversial results con-
cerning the association between apoE genotype and some
cardiovascular risk factors. Previous studies have sug-
gested that high blood pressure may be associated with
the presence of the ε4 allele [6,15,16], others have found
an association with ε2 allele and hypertension [7], and no
association were found in some studies [8-10]. ApoE may
interfere with smooth muscle cell proliferation [17] and
thus participate in smooth muscle cell hypertrophy in the
arterial wall. These mechanisms may explain the associa-
tion in young or middle-aged populations that were
mainly included in the previous studies. However, other
mechanisms such as increased rigidity and decreased elas-
ticity of the aorta and other large vessels [18] may
contribute to the development of high blood pressure,
and thus explain the lack of association in the very elderly.
Table 2: Blood lipids and APOE genotypes in the study population (N = 505). Mmol ± SD.
APOE Genotype Mean serum 
cholesterol
Mean serum 
triglycerides
Mean serum HDL Mean serum LDL
ε2/ε2 4.1 ± 1.2 1.7 ± 0.5 1.1 ± 0.4 2.2 ± 0.9
ε2/ε3 5.1 ± 1.2 1.9 ± 0.8 1.0 ± 0.3 3.2 ± 1.1
ε2/ε4 4.9 ± 0.9 1.4 ± 0.5 1.2 ± 0.3 3.1± 0.9
ε3/ε3 5.4 ± 1.3 2.0 ± 1.2 1.0 ± 0.3 3.6 ± 1.1
ε3/ε4 5.6 ± 1.2 2.0 ± 1.2 1.0 ± 0.3 3.8 ± 1.1
ε4/ε4 6.0 ± 2.1 1.4 ± 0.8 1.0 ± 0.2 4.3 ± 1.9
P 0.02 0.5 0.1 0.001
Table 3: APOE genotypes, atrial fibrillation and ECG abnormalities in the study population. Total number and percentages of total (N 
= 505).
APOE 
Genotype
Atrial 
fibrillation
No atrial 
fibrillation
VPB*or SVPB No VPB or 
SVPB
Conduction 
disturbances
No conduction 
disturbances
ε2/ε2 1(0.2) 1(0.2) 0(0) 2(0.4) 0(0) 2(0.4)
ε2/ε3 7(1.4) 53(10.5) 35(6.9) 26(5.1) 9(1.8) 52(10.3)
ε2/ε4 1(0.2) 13(2.6) 8(1.6) 6(1.2) 4(0.8) 10(2.0)
ε3/ε3 54(10.7) 240(47.5) 122(24.2) 173(34.3) 25(4.9) 269(53.3)
ε3/ε4 20(4.0) 107(21.2) 55(10.9) 70(13.9) 10(1.9) 116(23.0)
ε4/ε4 3(0.6) 5(0.9) 2(0.4) 6(1.1) 0(0) 8(1.6)
Total 86(17.0) 419(81.7) 222(43.7) 283(56.3) 48(9.4) 457(90.6)
P 0.06 0.1 0.1
* Abbreviations: VPB = ventricular premature beats SVPB = supraventricular premature beats Conduction disturbances include first and second 
degree atrioventricular block, left bundle branch block, right bundle branch blockBMC Geriatrics 2004, 4 http://www.biomedcentral.com/1471-2318/4/1
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In the present study, there was no relationship between
APOE genotype and blood pressure. Because CHD is a
well-known etiological factor for AF [19], we examined
the relationship between APOE genotype and ECG
changes. There were no statistically significant associa-
tions between ECG changes and APOE genotype. Previous
population-based studies have suggested that the ε4 allele
frequency is smaller in the elderly [20], possibly due to
increased mortality of the ε4 allele carriers [21]. The fre-
quency of the ε4 allele in the very elderly in the present
study was, however only slightly lower (15.3%) than pre-
viously shown frequency in the young Finnish subjects
(19.4%) [22]. The signs of CHD were not analysed on the
recordings, as resting ECG is not reliable for detection of
CHD. Thus the association between APOE genotypes and
the extent atherosclerotic process in the arteries cannot be
measured on the basis of our material. There are several
possible aetiologies for AF in this age group, some of
which are not associated with APOE polymorphism.
There were no statistically significant association between
other ECG changes and APOE genotypes.
These observations show that APOE genotype still influ-
ences cholesterol levels but not other cardiovascular risk
factors such as blood pressure among the very elderly.
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